Nachrichten zur Regeneron Pharmaceuticals Inc. Aktie

Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market

Shares of Regeneron Pharmaceuticals Inc. sank 0.01% to $876.00 Thursday, on what proved to be an all-around favorable trading session…

Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript)

…

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

The STRIDE study did not meet its primary or secondary efficacy endpoint…

Regeneron Pharmaceuticals: Neues Kursziel

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Morgan Stanley stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

Top 5 NASDAQ Genetics Stocks of 2023

The genetics sector supports every other life science industry in a variety of ways.One of its major contributions is the…

Top 5 NASDAQ Genetics Stocks (Updated March 2023)

The genetics sector supports every other life science industry in a variety of ways.One of its major contributions is the…

Regeneron Pharmaceuticals: Kursziel verbessert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von TD Cowen stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

: Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals

Replimune Group Inc. shares REPL dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer…

Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)

…

Regeneron Pharmaceuticals: Positive Ergebnisse aus der zweiten Phase-3-Studie für Dupixent - Aktienanalyse

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Jefferies & Co: Akash Tewari, Analyst von Jefferies & Co, stuft die Aktie von…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference (Transcript)

…

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Truist Securities BioPharma Symposium (Transcript)

…

Regeneron Pharmaceuticals Inc. (REGN) UBS Biopharma Conference (Transcript)

…

Regeneron Pharmaceuticals: Kursziel erhöht

Milwaukee (www.aktiencheck.de) - Rating-Update: Die Analysten von Robert W. Baird stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

Regeneron Pharmaceuticals: Neues Kursziel

London (www.aktiencheck.de) - Rating-Update: Barclays stuft die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) weiterhin…

Regeneron Pharmaceuticals: Canaccord erhöht Kursziel und rät zum Kauf - Aktienanalyse

Vancouver (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Canaccord Genuity: Die Analysten von Canaccord Genuity stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN:…

Regeneron Pharmaceuticals: Hochstufung! Positive Dynamik bis 2024 erwartet - Aktienanalyse

St. Petersburg (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Raymond James: Dane Leone, Analyst von Raymond James, stuft in einer aktuellen Aktienanalyse die…

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2023 Earnings Call Transcript

…

Regeneron Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Regeneron Reports Third Quarter 2023 Financial and Operating Results

TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for…

Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop

…

How to Invest in Genetics (Updated 2023)

Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on…

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as…

Aktie von Regeneron Pharmaceuticals läuft heute schlechter (750,7140 €)

Die Aktie von Regeneron Pharmaceuticals notiert heute ein wenig leichter. Zuletzt zahlten Investoren für das Wertpapier 799,11 US-Dollar. Heute hat…

Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

TARRYTOWN, N.Y. and PARIS, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today…

Regeneron Pharmaceuticals: "buy"

Vancouver (www.aktiencheck.de) - Rating-Update: Die Analysten von Canaccord Genuity bewerten die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol:…

Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit

IRVINE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company…

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics,…

Regeneron Pharmaceuticals: BofA erhöht Kursziel - Aktienanalyse

Charlotte (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von BofA Securities: Die Analysten von BofA Securities stufen in einer aktuellen Aktienanalyse die Aktie von…

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will…

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has…

Transforming Skin Care: Atopic Eczema Treatment Market Size Predicted to Flourish to USD 13 Billion by 2030, with a 7.14% CAGR

[219 + Pages Report] According to a market research study published by Zion Market Research, the demand analysis of Global…

Regeneron Pharmaceuticals: Neues Kursziel

New York (www.aktiencheck.de) - Rating-Update: Jasper Hellweg, Analyst von Argus Research, stuft die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN:…